Vertex Pharmaceuticals Inc. (VRTX) News Headlines

▮ More

Date

Headline

12/8/2022 7:46:14 AM Vertex, Entrada To Develop Endosomal Escape Vehicle Therapeutics For Myotonic Dystrophy Type 1

12/8/2022 7:04:58 AM Vertex And Entrada To Discover And Develop Endosomal Escape Vehicle Therapeutics For Myotonic Dystrophy Type 1

10/27/2022 4:26:22 PM Vertex Pharmaceuticals Inc. (VRTX) Has Raised Its 2022 Revenue Estimate To $8.8 to $8.9 Bln From $8.6 to $8.8 Bln

10/27/2022 4:25:35 PM Vertex Pharmaceuticals Inc. Q3 Profit Advances

10/27/2022 4:13:42 PM Vertex Pharma Q3 EPS $3.59 Vs. $3.28 Year Ago

8/4/2022 4:42:31 PM Vertex Pharmaceuticals Inc. Reveals Rise In Q2 Bottom Line

8/4/2022 4:41:47 PM Vertex Pharmaceuticals Lifts FY22 Product Revenue Outlook

8/4/2022 4:40:02 PM Vertex Pharmaceuticals Inc. (VRTX) Has Raised Its FY22 Revenue Estimate To $8.6 to $8.8 Bln From $8.4 to $8.6 Bln

8/4/2022 4:14:34 PM Vertex Pharma Q2 EPS $3.13 Vs. $0.26 Year Ago

8/4/2022 3:00:17 PM Vertex Pharmaceuticals Q2 22 Earnings Conference Call At 4:30 PM ET

7/11/2022 8:25:59 AM Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

7/11/2022 8:05:10 AM Vertex To Acquire ViaCyte For $320 Mln In Cash

7/5/2022 8:10:22 AM Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

7/5/2022 8:02:54 AM Vertex : FDA Lifts Clinical Hold On VX-880 Phase 1/2 Trial For Treatment Of Type 1 Diabetes

6/15/2022 3:00:59 PM Vertex Pharma To Present At Goldman Sachs Global Healthcare Conference; Webcast At 4:20 PM ET

6/8/2022 8:37:06 AM Vertex Pharma: FDA Grants Inaxaplin Breakthrough Therapy Designation

6/8/2022 8:03:42 AM Vertex's Inaxaplin Granted Breakthrough Therapy Designation By FDA And Priority Medicines Designation By EMA

6/2/2022 10:21:57 AM Vertex And CRISPR Announce Acceptance Of Late-Breaking Abstract For CTX001 At 2022 Annual EHA Congress

5/31/2022 8:07:48 AM Vertex To Present New Data On VX-880 Clinical Trial

5/5/2022 4:26:21 PM Vertex Pharma Q1 EPS $2.96 Vs. $2.49 Year Ago